By By Ankit Kankar | June 22, 2026
Karsten Eastman, Co-founder and CEO of Sethera Therapeutics, discusses peptide therapeutics, translational discipline, precision oncology, and why the industry’s future will be defined by product credibility rather than platform promises.
Cancer drug discovery is entering a more disciplined era. Investors, partners, and clinicians are increasingly focused on therapeutic approaches that can demonstrate clear clinical relevance, strong translational rationale, and practical paths to development. At the same time, advances in peptide engineering, targeted delivery systems, and computational drug discovery are expanding the range of previously inaccessible oncology targets. In this conversation with BioSpectrum Asia during BIO International Convention 2026, Karsten Eastman, Co-founder and CEO of Sethera Therapeutics, shares his perspectives on the evolution of precision oncology, the growing promise of constrained peptide therapeutics, and the key trends shaping the next generation of cancer innovation.